07-606 | Anti-phospho-JAK2 (Tyr1007/1008) Antibody

200 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, RWBRbPurifiedPolyclonal Antibody
      Catalogue Number07-606
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-phospho-JAK2 (Tyr1007/1008) Antibody
      Alternate Names
      • Janus kinase 2
      • Janus kinase 2 (a protein tyrosine kinase)
      • tyrosine-protein kinase JAK2
      Background InformationJAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor. Among a variety of sites, Tyrosines 1007 and 1008 are sites of trans- or autophosphorylation in vivo and in in vitro kinase reactions.
      Product Information
      • Human ovarian cancer cells, GM-CSF-treated TF-1 cells.
      PresentationPurified rabbit IgG in buffer containing 0.1M Tris-Glycine, 0.15M NaCl, 0.05% Sodium Azide, pH7.4.
      ApplicationAnti-phospho-JAK2 (Tyr1007/1008) Antibody detects level of phospho-JAK2 (Tyr1007/1008) & has been published & validated for use in WB.
      Key Applications
      • Western Blotting
      Biological Information
      ImmunogenKLH-conjugated, synthetic peptide corresponding to amino acids surrounding phosphotyrosines 1007 and 1008 of human JAK2.
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      SpecificityRecognizes phosphorylated JAK2, Mr 130 kDa.
      Species Reactivity
      • Human
      • Mouse
      • Rat
      Species Reactivity NoteHuman and mouse. Predicted to cross-react with rat based on sequence homology.
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis.
      Gene Symbol
      • JAK2
      • OTTHUMP00000043260
      • JAK-2
      • Phosphorylation
      Purification MethodProtein A Purfied
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: O60674 # Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction.
      SIZE: 1132 amino acids; 130674 Da
      SUBUNIT: Interacts with SIRPA (By similarity). Interacts with IL23R, SKB1 and STAM2.
      SUBCELLULAR LOCATION: Intracytoplasmic membrane; Peripheral membrane protein (By similarity). Note=Wholly intracellular, possibly membrane associated (By similarity).
      TISSUE SPECIFICITY: Expressed in blood, bone marrow and lymph node.
      DOMAIN: SwissProt: O60674 Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.
      DISEASE: SwissProt: O60674 # Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6. & Defects in JAK2 are a cause of susceptibility to Budd- Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites. & Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients. & Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications. & Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension. & Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
      SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily. & Contains 1 FERM domain. & Contains 1 protein kinase domain. & Contains 1 SH2 domain.
      Molecular Weight130 kDa
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceRoutinely evaluated by Western Blot on Pervanadate treated L6 lysates.

      Western Blot Analysis:
      1:500 dilution of this lot detected PHOS-JAK2 (TYR1007/1008) on 10 ug of Pervanadate treated L6 lysates.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at 2-8°C from date of receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
      Packaging Information
      Material Size200 µg
      Transport Information
      Supplemental Information




      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-phospho-JAK2 (Tyr1007/1008) - 2391090 2391090
      Anti-phospho-JAK2 (Tyr1007/1008) - 1962652 1962652
      Anti-phospho-JAK2 (Tyr1007/1008) - 2073140 2073140
      Anti-phospho-JAK2 (Tyr1007/1008) - 2266823 2266823
      Anti-phospho-JAK2 (Tyr1007/1008) - 27029 27029
      Anti-phospho-JAK2 (Tyr1007/1008) - 30220 30220
      Anti-phospho-JAK2 (Tyr1007/1008) - 3067446 3067446
      Anti-phospho-JAK2 (Tyr1007/1008) - DAM1718078 DAM1718078
      Anti-phospho-JAK2 (Tyr1007/1008) - DAM1778035 DAM1778035
      Anti-phospho-JAK2 (Tyr1007/1008) -2521452 2521452


      Reference overviewApplicationSpeciesPub Med ID
      Phosphorylation of the adaptor protein SH2B1β regulates its ability to enhance growth hormone-dependent macrophage motility.
      Su, HW; Lanning, NJ; Morris, DL; Argetsinger, LS; Lumeng, CN; Carter-Su, C
      Journal of cell science  126  1733-43  2013

      Show Abstract
      23444381 23444381
      Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
      Wan, X; Ma, Y; McClendon, CL; Huang, LJ; Huang, N
      PLoS computational biology  9  e1003022  2013

      Show Abstract
      23592968 23592968
      A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.
      Jatiani, SS; Cosenza, SC; Reddy, MV; Ha, JH; Baker, SJ; Samanta, AK; Olnes, MJ; Pfannes, L; Sloand, EM; Arlinghaus, RB; Reddy, EP
      Genes & cancer  1  331-45  2010

      Show Abstract
      Western Blotting20717479 20717479
      JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells.
      Jin, H; Lanning, NJ; Carter-Su, C
      Molecular endocrinology (Baltimore, Md.)  22  1825-41  2008

      Show Abstract Full Text Article
      18499741 18499741
      Oxysterol and diabetes activate STAT3 and control endothelial expression of profilin-1 via OSBP1.
      Romeo, GR; Kazlauskas, A
      The Journal of biological chemistry  283  9595-605  2008

      Show Abstract
      Western BlottingRat18230613 18230613
      {alpha}-Syntrophin regulates ARMS localization at the neuromuscular junction and enhances EphA4 signaling in an ARMS-dependent manner
      Luo, S., et al
      J Cell Biol, 169:813-24 (2005)  2005

      Immunoblotting (Western)15939763 15939763
      Requirement of Ca(2+) and PKCdelta for Janus kinase 2 activation by angiotensin II: involvement of PYK2.
      Frank, Gerald D, et al.
      Mol. Endocrinol., 16: 367-77 (2002)  2002

      Show Abstract
      11818507 11818507
      Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
      Xie, S, et al.
      Oncogene, 20: 6188-95 (2001)  2001

      Show Abstract
      11593427 11593427

      Technical Info

      JAK/STAT Signaling Research Focus

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      04-001 Anti-JAK2 Antibody, clone 8E10.2 Show Pricing & Availability
      06-255 Anti-JAK2 Antibody Show Pricing & Availability
      09-203 Anti-phospho-JAK2 (Tyr868) Antibody Show Pricing & Availability
      09-241 Anti-phospho JAK-2 (Tyr570) Antibody Show Pricing & Availability
      09-243 Anti-phospho JAK2 (Tyr972) Antibody Show Pricing & Availability
      09-275 Anti-phospho-JAK2 (Tyr1007/1008) Antibody Show Pricing & Availability
      16-121 Anti-JAK2 Antibody, agarose conjugate Show Pricing & Availability
      MABS809 Anti-JAK2, clone 1C1 Antibody Show Pricing & Availability

      Product Families


      Life Science Research > Antibodies and Assays > Primary Antibodies